粵港灣控股(01396.HK):尚未償還2021年到期優先票據交換要約延遲截止期限
格隆匯10月5日丨粵港灣控股(01396.HK)發佈公吿,有關尚未償還的14.00% 2021年到期的優先票據的交換要約,由即時起,截止期限由2021年10月4日下午四時正(倫敦時間)延遲至2021年10月7日下午四時正(倫敦時間)。已有效提交票據的合資格持有人於原截止期限或之前無需採取任何行動。有關交換要約的指示仍為有效及不可撤銷。
尚未提交現有票據的合資格持有人可根據交換要約備忘錄所載條款及條件於延遲截止期限或之前提交現有票據。有關交換要約的指示均不可撤銷。待完成交換要約,公司將於延遲截止期限或之前就有效提交的現有票據及獲接納交換支付交換要約備忘錄所載交換代價。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.